Weighing the Tradeoffs at RosettaFest
Few topics have generated more discussion among employers than GLP-1 coverage. Once, the question was whether to cover these therapies at all. Today, as utilization continues to grow and new delivery models emerge, the conversation has shifted. The challenge is no longer deciding if obesity care belongs in an employer’s benefit strategy. It’s determining how to structure coverage in a way that balances access, affordability and long-term value.
At RosettaFest 2026, WellDyne and HealthDyne leaders will explore the evolving landscape and the approaches shaping today’s market. From lifestyle-focused programs and direct-to-consumer or direct-to-employer solutions to integrated benefit management, each model was built to solve a different problem. Understanding the value and tradeoffs behind each approach is becoming just as important as the coverage decision itself.
Weighing the Tradeoffs in GLP-1 Coverage
RosettaFest 2026
Wednesday, July 29 | 4:00 pm CST
Presented by:
– Rich Wipperfurth, Chief Commercial Officer, WellDyne
– Nick Page, Chief Clinical Officer, WellDyne
– Sarah Thomas, SVP Growth & Commercialization, HealthDyne
“The market has given employers more choices than ever before,” said Rich Wipperfurth, Chief Commercial Officer at WellDyne. “Some models are built to make GLP-1s easier to access. Others focus on changing behaviors or managing costs. None of those goals are wrong. The question is which one matters most to your organization.”
Rather than debating which model is “best,” the session will examine the broader strategy behind each approach. As acquisition costs evolve and employers gain greater flexibility in how they design coverage, the conversation is shifting beyond pharmacy spend alone. Clinical alignment, benefit design, transparency and total cost of care all play a role in determining long-term success.
“Obesity is a chronic condition that affects far more than the pharmacy benefit,” said Nick Page, Chief Clinical Officer at WellDyne. “If the right patients aren’t getting effective treatment, you may simply be shifting costs from the pharmacy benefit to the medical benefit. The goal is making sure pharmacy dollars are invested where they can have the greatest impact.”
Bringing together expertise from pharmacy benefits, clinical strategy and patient access, the session will also highlight how employers can think differently about obesity care by connecting benefit design with member needs and organizational priorities.
“Direct-to-employer models have changed the conversation,” said Sarah Thomas, SVP of Growth & Commercialization at HealthDyne. “They give employers new flexibility in how they structure benefits, fund coverage and improve cost transparency.”
Because when the stakes—and spend—are this high, the smartest strategy isn’t choosing a side. It’s understanding the tradeoffs, aligning benefits to your goals and measuring what matters.
